APA (7th ed.) Citation

Foley, A., Leach, M., Averion, G., Hu, Y., Yun, P., Neuhaus, S., . . . Bönnemann, C. (2018). CONGENITAL MUSCULAR DYSTROPHIES: P.329CALLISTO: a phase I open-label, sequential group, cohort study of pharmacokinetics and safety of omigapil in LAMA2 and COL6-related dystrophy patients. Neuromuscular Disorders, 28, S129. https://doi.org/10.1016/j.nmd.2018.06.377

Chicago Style (17th ed.) Citation

Foley, A.R, et al. "CONGENITAL MUSCULAR DYSTROPHIES: P.329CALLISTO: A Phase I Open-label, Sequential Group, Cohort Study of Pharmacokinetics and Safety of Omigapil in LAMA2 and COL6-related Dystrophy Patients." Neuromuscular Disorders 28 (2018): S129. https://doi.org/10.1016/j.nmd.2018.06.377.

MLA (9th ed.) Citation

Foley, A.R, et al. "CONGENITAL MUSCULAR DYSTROPHIES: P.329CALLISTO: A Phase I Open-label, Sequential Group, Cohort Study of Pharmacokinetics and Safety of Omigapil in LAMA2 and COL6-related Dystrophy Patients." Neuromuscular Disorders, vol. 28, 2018, p. S129, https://doi.org/10.1016/j.nmd.2018.06.377.